| h-debate-ce7761a039f | MAPT Transcriptional Control | 0.00 | 0.55 | MAPT | proposed | 2026-04-28 | sda-2026-04-01-gap-005 |
| h-debate-baba8b6100d | Chromatin Remodeling for Tau-Associated Gene Expression | 0.00 | 0.55 | HDAC1 | proposed | 2026-04-28 | sda-2026-04-01-gap-005 |
| h-debate-c3b0e62f7b7 | NRF2 Pathway Activation for Neuroprotection | 0.00 | 0.55 | NFE2L2 | proposed | 2026-04-28 | sda-2026-04-01-gap-005 |
| h-debate-31b1db1e857 | Autophagy Enhancement for Tau Clearance | 0.00 | 0.55 | ATG7 | proposed | 2026-04-28 | sda-2026-04-01-gap-005 |
| h-debate-bb090684c56 | Exosomal Autophagosome Transfer System | 0.00 | 0.55 | LC3B | proposed | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062212-b66510d9 |
| h-debate-957d23cf0d2 | Astrocytic SQSTM1 Overexpression Therapy | 0.00 | 0.55 | SQSTM1 | proposed | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062212-b66510d9 |
| h-debate-906054055bd | Oligodendroglial Autophagy Enhancement | 0.00 | 0.55 | ATG7 | proposed | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062212-b66510d9 |
| h-debate-74d4cecf482 | Trehalose-Resistant Autophagy Bypass Pathway | 0.00 | 0.55 | ULK1 | proposed | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062212-b66510d9 |
| h-debate-ce3e7a9a3fc | Microglial Autophagy Priming Therapy | 0.00 | 0.55 | MTOR | proposed | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062212-b66510d9 |
| h-debate-ca96b340b8b | Intercellular Mitophagy Communication Network | 0.00 | 0.55 | PINK1 | proposed | 2026-04-28 | SDA-2026-04-08-gap-pubmed-20260406-062212-b66510d9 |
| h-debate-2ac2b576b08 | Stress-Activated Retrotransposon Epigenetic Regulation (SARER) | 0.00 | 0.55 | TRIM28 | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062039-f02efa4b |
| h-debate-da4bd95f955 | Temporal Epigenetic Switch Points (TESP) | 0.00 | 0.55 | CLOCK | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062039-f02efa4b |
| h-debate-6077bb292cf | Paracrine Epigenetic Signaling Networks (PESN) | 0.00 | 0.55 | miR-155 | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062039-f02efa4b |
| h-debate-1ea5d1f402c | Stress-Responsive Epigenetic Memory (SREM) | 0.00 | 0.55 | EZH2 | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062039-f02efa4b |
| h-debate-748b48b3a83 | Mechanosensitive Epigenetic Transcription (MET) | 0.00 | 0.55 | YAP1 | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062039-f02efa4b |
| h-debate-5d2bedefac8 | Convergent Chromatin Remodeling Cascade (CRC) | 0.00 | 0.55 | HDAC2 | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062039-f02efa4b |
| h-debate-a541706ec31 | Metabolic-Epigenetic Coupling Interface (MECI) | 0.00 | 0.55 | SIRT1 | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062039-f02efa4b |
| h-debate-555b51502d8 | TREM2 Gradient-Based Drug Delivery | 0.00 | 0.55 | TREM2 | proposed | 2026-04-28 | trem2-ad |
| h-debate-eec38ce2041 | TREM2-Mediated Fibrotic Prevention in Neurodegeneration | 0.00 | 0.55 | TREM2 | proposed | 2026-04-28 | trem2-ad |
| h-debate-ce48afac076 | Immunological Niche Transition Targeting | 0.00 | 0.55 | TREM2 | proposed | 2026-04-28 | trem2-ad |
| h-debate-5435d088817 | Combination Therapy: TREM2 + T-cell Modulation | 0.00 | 0.55 | TREM2 | proposed | 2026-04-28 | trem2-ad |
| h-debate-639e4a0edb2 | Metabolic Reprogramming via TREM2-Mitochondrial Axis | 0.00 | 0.55 | TREM2 | proposed | 2026-04-28 | trem2-ad |
| h-debate-b4ed155766a | TREM2-Apoptosis Axis for Cellular Clearance | 0.00 | 0.55 | TREM2 | proposed | 2026-04-28 | trem2-ad |
| h-debate-1a22e13feff | Temporal TREM2 Modulation for Alzheimer's Therapy | 0.00 | 0.55 | TREM2 | proposed | 2026-04-28 | trem2-ad |
| h-debate-adcc46636df | Adaptive Deep Brain Stimulation Targeting the Pedunculopontine Nucleus | 0.00 | 0.55 | GBA | proposed | 2026-04-28 | gba-pd |
| h-debate-ebaf8669e5a | Lysosomal Membrane Stabilization as Upstream GBA Therapy | 0.00 | 0.55 | GBA | proposed | 2026-04-28 | gba-pd |
| h-debate-624ccea7e1e | Neuroinflammation Biomarker-Guided Immunomodulation for GBA Carriers | 0.00 | 0.55 | IL1B | proposed | 2026-04-28 | gba-pd |
| h-debate-2cd6bbdefea | Combinatorial TFEB Activation and Anti-Inflammatory Therapy | 0.00 | 0.55 | TFEB | proposed | 2026-04-28 | gba-pd |
| h-debate-4ab1496bc9a | Personalized DBS Programming Based on GBA Genotype-Specific Neural Signatures | 0.00 | 0.55 | GBA | proposed | 2026-04-28 | gba-pd |
| h-debate-456c4d12c8e | Freezing-of-Gait Prediction Algorithm Using GBA Mutation Status | 0.00 | 0.55 | GBA | proposed | 2026-04-28 | gba-pd |
| h-debate-28a19fae67c | TFEB-Mediated Autophagy Enhancement as a Circuit Breaker for the GBA-Synuclein L | 0.00 | 0.55 | TFEB | proposed | 2026-04-28 | gba-pd |
| h-debate-329991626a9 | pH-Sensitive Tau Vesicle Targeting | 0.00 | 0.55 | MAPT | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-c4385a075de | Vesicle Surface Glycan Pattern Recognition | 0.00 | 0.55 | MAPT | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-810c1e5a5ac | Tau-Induced Lipid Membrane Asymmetry Exploitation | 0.00 | 0.55 | MAPT | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-f7e4ecbf7b3 | Tau Conformational State-Specific Nanobody Targeting | 0.00 | 0.55 | MAPT | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-16810224092 | Tau Post-Translational Modification State Targeting | 0.00 | 0.55 | MAPT | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-e52f9e63944 | Chaperone Co-localization Guided Delivery | 0.00 | 0.55 | HSPA1A | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-05624b1daee | Autophagosome Marker Hijacking Strategy | 0.00 | 0.55 | MAP1LC3A | proposed | 2026-04-28 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| h-debate-075de316a0b | Glial Scar Architecture Manipulation for Functional Compartmentalization | 0.00 | 0.55 | ARAP3, cytoskeletal regulators | proposed | 2026-04-28 | astrocyte-subtypes |
| h-debate-3cd1c9d33ea | Nrf2-NF-κB Oscillatory Circuit Modulation | 0.00 | 0.55 | NFE2L2, NFKB1 | proposed | 2026-04-28 | astrocyte-subtypes |
| h-debate-10f2f867bba | Nascent Transcript Targeting for Real-Time Reprogramming | 0.00 | 0.55 | RNA processing machinery | proposed | 2026-04-28 | astrocyte-subtypes |
| h-debate-cfec1a7354a | Temporal mTOR Modulation for Sequential A1/A2 Switching | 0.00 | 0.55 | MTOR | proposed | 2026-04-28 | astrocyte-subtypes |
| h-debate-49e9c1f5eca | Combinatorial Il-1α/TNFα/C1q Antagonism with Selective Agonism | 0.00 | 0.55 | IL1A, TNF, C1QA, NFE2L2 | proposed | 2026-04-28 | astrocyte-subtypes |
| h-debate-dfbbb1f6b9f | Microglial GLP-1R-Mediated Astrocyte Programming | 0.00 | 0.55 | GLP1R, ARAP3 | proposed | 2026-04-28 | astrocyte-subtypes |
| h-debate-698ff0b1f07 | Age-Stratified Astrocyte Subtype Switching | 0.00 | 0.55 | Multiple age-dependent switches | proposed | 2026-04-28 | astrocyte-subtypes |
| h-debate-68fd2b81578 | Bi-directional Transcytosis Inhibition Strategy | 0.00 | 0.55 | ABCB1 (P-glycoprotein), ABCG2 (BCRP), APP/Aβ | proposed | 2026-04-28 | sda-2026-04-01-gap-008 |
| h-debate-24170addd30 | Intranasal Delivery of BBB-Penetrating Antibody Conjugates | 0.00 | 0.55 | APP/Aβ, olfactory receptor neurons | proposed | 2026-04-28 | sda-2026-04-01-gap-008 |
| h-debate-477286ec859 | Engineered Exosome-Encapsulated Antibody Fragments | 0.00 | 0.55 | APP/Aβ, TFRC, lactoferrin receptor | proposed | 2026-04-28 | sda-2026-04-01-gap-008 |
| h-debate-a513718a3ee | Cell-Penetrating Peptide Conjugated Nanobodies | 0.00 | 0.55 | APP/Aβ oligomers, various CPP sequences | proposed | 2026-04-28 | sda-2026-04-01-gap-008 |
| h-debate-72a94a5767c | LRP1-Mediated Trojan Horse Delivery System | 0.00 | 0.55 | LRP1 (low-density lipoprotein receptor-related protein 1), A | proposed | 2026-04-28 | sda-2026-04-01-gap-008 |